The AJMC® Asthma compendium is a comprehensive resource for clinical news and expert insights for the chronic lung disease.
May 16th 2024
Underlying mood and sleep disorders may negatively affect asthma control, researchers find.
Evolving Treatment Strategies in the Management of Pulmonary Arterial Hypertension: Key Insights for the Pharmacist, featuring a Patient Perspective
1.5 Credits / Pulmonology/Respiratory
View More
Advances in EGFR Exon 20 Insertion-Positive Non–Small Cell Lung Cancer: A Focus on Specialty Pharmacy Interventions
1.5 Credits / Oncology, Pulmonology/Respiratory
View More
Advances and Best Practices for Managed Care Pharmacists and the Treatment of Patients with Alpha-1 Antitrypsin Deficiency
1.0 Credit / Pulmonology/Respiratory
View More
Dupilumab Safe, Effective Among Patients With Comorbid Asthma, CRSwNP
July 11th 2022Although approved for use among patients with severe or refractory asthma, few studies have investigated its effectiveness among patients with comorbid mild to moderate asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
Read More
Dupilumab Demonstrates Safety, Efficacy Across Several Type 2 Inflammatory Diseases
July 2nd 2022Research presented at the European Academy of Allergy and Clinical Immunology Annual Congress show the safety and efficacy of dupilumab across several progressive diseases with underlying type 2 inflammation, including eosinophilic esophagitis (EoE), severe asthma, and severe chronic rhinosinusitis with nasal polyps.
Read More
Clinical and Economic Burden of Uncontrolled Severe Noneosinophilic Asthma
Among patients with severe asthma with low eosinophils untreated with biologics, there is a high burden of disease among those who have suboptimal disease control.
Read More
Caregivers of Children With Asthma Lack Knowledge About Disease Management
June 22nd 2022About 70% of caregivers studied reported that they preferred to use the emergency department for treatment for asthma exacerbations, indicating current education is insufficient for managing asthma at home.
Read More
Dupilumab Efficacy in Asthma, AD, EoE, and CRSwNP Not Affected By Eosinophil Count
June 8th 2022Dupilumab-induced increases in mean eosinophil counts were shown to wane over time in patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and atopic dermatitis (AD), with incidence of eosinophilia not shown to reduce efficacy of the biologic.
Read More
Dupilumab Reduces OCS Dosage, Improves Lung Function for Asthma, CRSwNP
May 22nd 2022Dupilumab was associated with reductions in exacerbations and oral corticosteroids (OCS) dosage, as well as improved lung function, in patients with OCS-dependent asthma with and without comorbid chronic rhinosinusitis with nasal polyps.
Read More
Biologics Provide Opportunity to Manage Moderate to Severe Pediatric Asthma, Improve QOL
May 13th 2022Pediatric patients with asthma and their caregivers are faced with significant health and cost burdens, and biologics provide an opportunity to improve quality of life and asthma control, according to a panel of experts.
Read More
Improved Sense of Smell Achieved With Biologics for CRS With Nasal Polyps, Asthma
May 12th 2022Patients with comorbid chronic rhinosinusitis (CRS) with nasal polyps and severe asthma reported significant improvement in their sense of smell when treated with the biologics omalizumab, mepolizumab, reslizumab, or benralizumab, with no significant differences observed between the treatment groups.
Read More
Clinical Improvement of AERD Achieved With Dupilumab Use for Asthma, CRS With Nasal Polyps
May 3rd 2022Patients with aspirin-exacerbated respiratory disease (AERD) who initiated treatment with dupilumab as an add-on asthma or chronic rhinosinusitis with nasal polyps therapy reported rapid clinical improvement that was sustained after 3 months.
Read More
Study Examines Impact of Biologics for Asthma on HCRU
April 21st 2022The research, conducted in Germany, found that biologic treatment for asthma resulted in reduced health care resource utilization (HCRU), as seen in fewer hospitalizations and oral corticosteroid prescriptions as well as less sick leave.
Read More
Severe Uncontrolled Asthma Results in Higher Economic Burden Despite Treatment With Biologics
March 31st 2022Patients with severe asthma continue to have residual disease despite initiating treatment with biologics, and severe uncontrolled asthma is associated with higher economic burden compared with controlled asthma, according to 2 posters.
Read More